FCM Stock Overview
Engages in the research, development, and production of original and generic pharmaceutical products for human and veterinary use in Italy.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Friulchem S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.77 |
| 52 Week High | €1.12 |
| 52 Week Low | €0.72 |
| Beta | 0.53 |
| 11 Month Change | 1.32% |
| 3 Month Change | -3.75% |
| 1 Year Change | -25.24% |
| 33 Year Change | -40.54% |
| 5 Year Change | -54.71% |
| Change since IPO | -55.80% |
Recent News & Updates
Shareholder Returns
| FCM | IT Pharmaceuticals | IT Market | |
|---|---|---|---|
| 7D | 0% | -1.1% | -2.1% |
| 1Y | -25.2% | 7.7% | 11.9% |
Return vs Industry: FCM underperformed the Italian Pharmaceuticals industry which returned 9.3% over the past year.
Return vs Market: FCM underperformed the Italian Market which returned 15.9% over the past year.
Price Volatility
| FCM volatility | |
|---|---|
| FCM Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in IT Market | 7.0% |
| 10% least volatile stocks in IT Market | 2.4% |
Stable Share Price: FCM has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: FCM's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 91 | Disma Mazzola | www.friulchem.com |
Friulchem S.p.A. engages in the research, development, and production of original and generic pharmaceutical products for human and veterinary use in Italy. It offers generic cosmoceuticals and food supplements; and chewable cubes for animals. The company was founded in 1996 and is based in Milan, Italy.
Friulchem S.p.A. Fundamentals Summary
| FCM fundamental statistics | |
|---|---|
| Market cap | €4.62m |
| Earnings (TTM) | -€314.36k |
| Revenue (TTM) | €30.51m |
0.2x
P/S Ratio-14.7x
P/E RatioIs FCM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FCM income statement (TTM) | |
|---|---|
| Revenue | €30.51m |
| Cost of Revenue | €23.19m |
| Gross Profit | €7.32m |
| Other Expenses | €7.63m |
| Earnings | -€314.36k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.052 |
| Gross Margin | 23.99% |
| Net Profit Margin | -1.03% |
| Debt/Equity Ratio | 135.8% |
How did FCM perform over the long term?
See historical performance and comparison